eli lilly new glp 1 Lilly's oral GLP-1 pill may help people with Type 2 diabetes lose 'significant' weight, study finds Lilly hikes revenue forecast by

S2CID 11525439

doi: 10.1186/s12902-023-01442-y

Intake routing, record storage, and administrative messaging occur before medical decisions are made

Nutritional support during GLP-1 treatment cannot be overstated

Investors are focusing on companies developing novel GLP-1, dual agonist, and multi-receptor therapies, while pharmaceutical manufacturers continue to invest heavily in production capacity and strategic acquisitions to strengthen their obesity and diabetes portfolios

[DOI] [PMC free article] [PubMed] [Google Scholar] 93.Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA